2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1802 Contemporary outcomes of autologous stem cell transplantation for mantle cell lymphoma in first remission: An EBMT lymphoma working party study of more than 10,000 patients

Iman Abou Dalle, MD, Maud Ngoya2, Yasmina Serroukh3, Patrice Chevallier4, Anne Huynh5, Marek Trnený, MD, CSc, Prof.6, Hervé Ghesquières, MD, PhD7, Grzegorz Helbig8, Charles Herbaux, MD, PhD9, Raynier Devillier, PhD10, Katherine Clesham11, Igor Wolfgang Blau12, Thomas Pabst13, Robert Zeiser14, François-Xavier Gros, MD15, Raffaella Cerretti, MD16, Linde Morsink17, Esra Gulderen18, Peter Dreger, Prof. Dr. med.19, Olivier Hermine, MD, PhD20, Ali Bazarbachi21
1 American University of Beirut, Beirut, Lebanon
2 EBMT statistical unit, Paris, France
3 Erasmus MC Cancer Institute, Rotterdam, Netherlands
4 Nantes University Hospital, Nantes, France
5 CHU de Toulouse Institut Universitaire du Cancer - Toulouse Oncopole, Toulouse, France
6 Charles University and General Hospital, Prague, Czech Republic
7 Hopital Lyon Sud HCL, Pierre Benite, Lyon, France
8 Silesian Medical Academy, Katowice, Poland
9 Hématologie Clinique, CHU Montpellier, Montpellier, France
10 Institut Paoli-Calmettes, Aix Marseille University, Marseille, France
11 University College London Hospital, London, United Kingdom
12 Medizinische Klinik m. S. Hamatologie , Onkologie und Tumorimmunologie, Berlin, Germany
13 University Hospital Bern, University of Bern, Bern, Switzerland
14 University of Freiburg, Freiburg, Germany
15 CHU Bordeaux, Hopital Haut-Leveque, Pessac, France
16 Tor Vergata University of Rome, Rome, Italy
17 Rijks Universiteit Groningen (RUG), Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
18 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
19 University of Heidelberg, Heidelberg, Germany
20 Hospital Necker, Paris, France
21 American University of Beirut, Beirut, Lebanon

Background: Autologous stem cell transplantation (auto-SCT) remains a standard consolidation strategy for eligible patients with mantle cell lymphoma (MCL) who achieve a first complete remission (CR) or partial  remission (PR) after frontline chemoimmunotherapy. However, the emergence of BTK-inhibitors (BTKi) have questioned the continued role of auto-SCT in the frontline setting. Nevertheless, there remains limited data on the contemporary outcomes of MCL patients undergoing auto-SCT consolidation after first CR/PR. We aimed to analyze temporal trends in the use of auto-SCT and assess survival outcomes according to transplant era.

Methods: This retrospective, registry-based study used data from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Adult patients (≥18 years) diagnosed with MCL who underwent auto-SCT in CR/PR within one year from diagnosis from 2011 to 2024 were included. Outcomes included overall survival (OS), progression-free survival (PFS), relapse incidence (RI), and non-relapse mortality (NRM). Multivariable Cox and competing-risk regression models evaluated prognostic factors, including 3 transplant eras to reflect changes in standard clinical practice: TE1: 2011-2013 (infrequent rituximab maintenance), TE2: 2014-2018 (adoption of rituximab maintenance), and TE3: 2019-2024 (more incorporation of BTKi).

Results: A total of 10,956 MCL patients were analyzed (median age: 59 years [interquartile range (IQR): 53-64]; 78% male). There were 2690 patients transplanted in TE1, 4017 in TE2, 4249 in TE3. The median time from diagnosis to auto-SCT was 6.7 months [IQR: 5.7-8.1]. Most patients had a Karnofsky performance score (KPS) ≥90 (80%). In more recent years, a greater proportion of patients with KPS<90 (21% versus 17%, p<0.0001), and high SCT-CI ≥3 (21% vs. 16%, p=0.0018) were transplanted.

At diagnosis, 80% of patients had stage IV disease. Extranodal involvement was present in 44% of patients, while 55% had involvement of ≥4 nodal sites. Classical MCL was the predominant histologic subtype (67%), followed by blastoid (20%), pleomorphic (7%), and indolent (6%). Overall, 73% underwent auto-SCT in CR, with the proportion of patients transplanted in CR increasing over time (67% in TE1, 72% in TE2, and 77% in TE3, p<0.0001). BEAM was the most used high-dose regimen (68%).

After a median follow-up of 3 years, the estimated 2-year OS and PFS were 89% (95% CI: 88-90) and 80% (95% CI: 79-81), respectively. The 2-year RI was 15% (95% CI: 14-16), whereas the 2-year NRM was 5% (4-5.2). Among patients transplanted in CR, outcomes improved significantly over time, with 2-year PFS increasing from 80.9% to 82.7% and 84.4%, across the three transplant eras (p <0.001), and a reduction in 2-year RI from 15.2% to 13.7% and 10.2%, respectively (p<0.001). Among patients transplanted in PR, 2-year PFS was 72% vs. 76% vs. 74% (p=0.03), while 2-year RI declined overtime (22.6% vs. 20% vs. 18%, p=0.005). The 2-year OS did not change overtime at 90% and 85% in CR and PR, respectively (p=0.24 and 0.08)

On multivariable analysis, auto-SCT in more recent years was independently associated with improved PFS in the overall cohort (hazard ratio (HR): 0.81 (95% CI: 0.75-0.87); p<0.001), and among CR patients (HR: 0.65 (95% CI: 0.55-0.78), p<0.001). Similarly, more recent transplant era was independently associated with a lower RI in the overall cohort (HR, 0.72; 95% CI, 0.66–0.78; p<0.001) and in patients transplanted in CR (HR, 0.54; 95% CI, 0.44–0.66; p<0.001). Older age, SCT-comorbidity index ≥ 3, PR at transplant, and high-dose regimen other than BEAM were independently associated with inferior PFS and OS. Male sex negatively affected PFS and KPS <90 negatively affected OS.

Conclusion: This is by far the largest study on auto-SCT for MCL in recent years and provides relevant information that could set the basis for prospective trials. The annual number of patients transplanted declined over time (897/year in TE1 to 708/year in TE3), a real world signal on BTKi impact. Survival outcomes after auto-SCT have continued to improve despite higher comorbidity burden. Patients transplanted in the contemporary era experienced significantly lower relapse rates and superior PFS, driven in part by more patients transplanted in CR. Ongoing studies incorporating measurable residual disease status and maintenance approaches will further define its role in the era of targeted therapies.

Iman Abou Dalle, MD: No relevant conflicts of interest to declare.